31 results about "Protein stabilization" patented technology

Interferon-β protein analogs in which the asparagine at position 25, numbered in accordance with native interferon-β, is deamidated exhibit a biological activity of native human interferon-β at an increased level and do not require HA for protein stabilization. The deamidated product is suitable for large scale manufacturing for incorporation in HA-containing or HA-free therapeutics for treatment of diseases including multiple sclerosis. An endoproteinase-C peptide map technique that produces a fingerprint profile for proteins using an enzymatic digest followed by RP-HPLC is also useful in quality control as an ID and / or quantitative test for the deamidated products.

The invention discloses a preparation method of low-fluorine Euphasia superb protein base stock. The preparation method comprises the following steps of: 1, low-temperature autolysis: homogenizing fresh and alive Euphasia superb and treating through ultraviolet irradiation to realize autolysis; 2, protein extraction: adding water into homogenate, stirring and extracting, carrying out centrifugal separation to obtain an upper-layer liquid phase and precipitates; 3, protein stabilization: refrigerating the upper-layer liquid for storage or drying the upper-layer liquid before refrigerating the upper-layer liquid for storage; 4, protein preparation: thawing the refrigerated upper-layer liquid; adjusting pH value to 4.8-5.8 or heating for 10-30 minutes at 80-100 DEG C and then centrifuging to obtain precipitate products and carrying out spray drying to finally obtain the Euphasia superb protein base stock. The preparation method is simple to operate and is quite suitable for field operation on a fishing ship; through adoption of the preparation method, the protein recovery rate is up to 46%-51% and the fat recovery rate is up to 54%-60%; and in the prepared low-fluorine Euphasia superb protein base stock, the protein content is 70-78% / 100g of dry base stock, the fat content is 25-31g / 100g of dry base stock and the fluorine content is lower than 1.5 mcg. / g of dry base stock.

The present invention provides methods and compositions for protein stabilization, particularly the stabilization of polymerases in aqueous solutions with cationic surfactants. The present invention further provides cationic surfactants, including polyethoxylated amines, that stabilize thermostable and thermolabile enzymes in solution. These surfactants stabilize the activity of various enzymes, including thermostable DNA polymerases, thermolabile DNA polymerases and reverse transcriptases.

An electrospinning approach is disclosed for generating a dissolvable formulation of a reagent of interest in a nanoscale fiber medium. In one embodiment, the nanoscale fibers can incorporate and stabilize biological agents of interest, such as for storage at room temperature for extended periods. In one implementation, the fibers can be produced in a continuous manner and dissolve rapidly.

Provided are storage containers for proteinaceous pharmaceutical compositions which are characterized in, among other things, comprising (i) a wall portion, wherein an inner wall material thereof is selected from silica-coated glass, silicone-coated glass, polymers of non-cyclic olefins, cycloolefin polymers and cycloolefin / linear olefin copolymers and (ii) one or more closure portions not constituting part of the wall portion, and which contains a formulation of a protein. Also provided are new methods of storing proteinaceous compositions. In one aspect, the stored protein is characterized as having an amino-terminal gamma-carboxyglutamic acid (Gla) domain with 9-12 Gla residues.

Interferon-ss protein analogs in which the asparagine at position 25, numbered in accordance with native interferon-ss, is deamidated exhibit a biological activity of native human interferon-ss at an increased level and do not require HA for protein stabilization. The deamidated product is suitable for large scale manufacturing for incorporation in HA-containing or HA-free therapeutics for treatment of diseases including multiple sclerosis. An endoproteinase-C peptide map technique that produces a fingerprint profile for proteins using an enzymatic digest followed by RP-HPLC is also useful in quality control as an ID and / or quantitative test for the deamidated products.

This invention is a method of using a class of excipients for protein formulation to reduce and / or eliminate protein aggregation in solutions or solids. This class of compounds contains carbonyl group(s) to form Schiff base(s) with amino groups of proteins and also contains moieties to keep protein molecules spatially separated. This method has never been disclosed anywhere in the literature.